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Abstract
Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and diagnosed mainly at advanced stages.
Hematuria is the main symptom of this malignancy. The origin of the disease is unknown; however the
multipotent stem cell theory applies best to this case. Histology and immunohistochemistry shows a tumour which
is indistinguishable from small cell lung carcinoma (SCLC). Coexistence of SCCB with other types of carcinoma is
common. The staging system used is the TNM-staging of bladder transitional cell carcinoma. The treatment is
extrapolated from that of SCLC. However, many patients with SCCB undergo radical resection which is rarely
performed in SCLC. Patients with surgically resectable disease (< or = cT1-4aN0M0) should be managed with
multimodal therapy associating chemotherapy, surgery and/or radiotherapy. Neoadjuvant chemotherapy using four
chemotherapy cycles followed by radical cystectomy is the most effective therapeutic sequence. Patients with
unresectable disease (> or = cT4bN+M+) should be managed with palliative chemotherapy based on
neuroendocrine type regimens comprising a platinum drug (cisplatin in fit patients). The prognosis of the disease is
poor mainly in the case of pure small cell carcinoma. Other research programs are needed to improve the
outcome of SCCB.
Disease name
Small cell carcinoma of the bladder
Poorly differentiated neuroendocrine carcinoma of the
bladder
Definition
Small cell carcinoma of the bladder (SCCB) is a rare,
poorly differentiated neuroendocrine epithelial tumour
associated with a more aggressive behaviour and poorer
outcome than bladder transitional cell carcinoma
(TCC). It is mostly diagnosed at advanced stage and
generally believed to have a high metastatic potential.
Current knowledge of this disease is limited and was
based mainly on retrospective investigations. The disease
was initially described in 1981 by Cramer et al [1]. Blad-
der small cell carcinoma (SCC) is frequently found com-
bined with other histological forms of bladder cancer:
TCC, adenocarcinoma and squamous cell carcinoma
[2-10]. The pathogenesis of primary SCCB is unknown.
However, several hypotheses were proposed to explain
the origin of SCC in the bladder. The most important
hypothesis was: the origin of SCCB may be a multipo-
tential common stem cell. Treatment of SCCB is extra-
polated from the treatment of small cell lung carcinoma
(SCLC). This comprehensive review would provide a
real insight into the epidemiology, pathogenesis, diagno-
sis, staging, treatment, and prognosis of SCCB.
Literature review
We based our review on the MEDLINE database using
the key words ‘bladder cancer’, ‘small cell carcinoma’,
‘pathogenesis’, ‘diagnosis’, ‘treatment’,a n d‘prognosis’.
The research was performed since January 1980 up to
July 2011. Only one prospective phase II study was
reported in the English literature. Twenty retrospectives
studies including ≥ 20 patients have been reported.
There have also been several interesting case reports
and literature reviews.
Review
I - Epidemiology
Small cell cancer of the bladder is an extremely rare
bladder malignancy with a mean frequency of 0.7% and
a range between 0.35% and 1.8% [2-7]. The reported
incidence is less than 1-9/1,000,000 habitant. Since
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and reported in the literature up to July 2011. The
demographic characteristics of SCCB are similar to
those seen in patients with transitional cell carcinoma
(TCC). The majority of patients are male, with a mean
sex ratio equal to 5:1, and a range between 1:1 to 16:1
[2-8,10-15]. Most patients are in the sixth to seventh
decade. Mean age at time of first diagnosis is 67 years;
ranging between 32 to 91 years [5,8,11,12]. Like TCC,
SCCB is often associated with a smoking history (in 65
to 79% of the cases) [4,7-9]. White patients represent
the vast majority of cases (74% to 97% of cases) [5,9,12].
Table 1 summarizes the epidemiological and clinical
characteristics of SCCB.
II - Pathogenesis
Pathogenesis of SCCB is not well defined. However, sev-
eral hypotheses were proposed to explain the origin of
SCC in the bladder. The most important hypotheses
were: 1. malignant transformation of bladder neuroen-
docrine cells gives rise to bladder SCC. This hypothesis
was supported by the fact that neuroendocrine cells
were found previously in the urinary bladder [16]; 2.
SCCB arises from urothelial metaplastic changes [1,17];
and a third and more powerful theory suggests that the
origin of SCCB may be a multipotential common stem
cell that has the ability to differentiate into various cell
types depending on the influence of specific transforma-
tion or progression-related gene. This may explain the
Table 1 Demographics and clinical characteristics of patients with SCCB
Authors No Sex
ratio
Age
(range)
Smoking
history
(%)
White
race
(%)
Symptoms (%) Frequency
of SCC (%)
Percentage
of mixed
histology
Blomjous 1989
[2]
18 2.6:1 69 (50-
81)
- - Hematuria; Dysuria 0.48% 55.6%
Holmang 1995
[3]
25 2.5:1 71.2
(54-87)
- - Hematuria 0.7% 60%
Lohrisch 1999
[4]
14 1:1 - 79% - Hematuria (100%); Local pain (36%) 0.35% 50%
Iczkowski 1999
[11]
46 6.7:1 67 (32-
91))
-- - - -
Siefker-Radtke
2004 (MD
Anderson)[12]
88 3.3:1 68 (31-
87)
- 88% Hematuria - 79.5%
Cheng 2004[8] 64 3.3:1 66 (36-
35)
65% - Hematuria (88%) - 68%
Mangar 2004
[14]
14 6:1 74 (54-
91)
- - Hematuria (93%) - -
Choong 2005
[5]
(Mayo Clinic)
44 3:1 66.9
(47-88)
- 97.7% Hematuria (68.2%); Incidental finding (18%); Urinary
obstruction (6.8%); Dysuria (2.3%); Abdominal pain (2.3%);
Urinary tract infection (2.3%); Ectopic ACTH secretion (2.3%)
0.5% 38.6%
Abrahams 2005
[9]
51 4:1 67 (39-
87)
- 74% Haematuria (63%); Dysuria (12%); Abdominal pain (2%);
Urinary obstruction (2%); Weight loss (2%); Urinary tract
infection (2%)
- 88%
Bex 2005[10] 25 11.5:1 64 (40-
90)
- - - - 44%
Quek 2005[6] 25 3:1 68 (40-
82)
- - - 1% 30%
Mukesh 2008
[13]
20 3:1 68 - - - - -
Ismaili 2008[7] 14 16:1 60.5
(45-78)
78.5% - - 1.8% 64.3%
Bex 2009[15] 17 16:1 62 (44-
78)
- - - - 50%
Siefker-Radtke
2009 (MD
Anderson)[33]
30 14:2 66.2
(43.1-
81)
- - - - 43%
Bex 2010[40] 51 4.1:1 65 (57-
74)
- - - - 59%
Abbreviations. SCC = small cell carcinoma; No = number of patients
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of the immunohistochemical staining (cytokeratin and
endocrine markers) [18-20].
III - Clinical features
The clinical features of SCCB are similar to those of
bladder TCC and reflect the presence of a tumoral
mass. Gross hematuria is the most common symptom
in SCCB which was noted in 63 to 88% of the cases
[5,8,9,12]. Dysuria has been reported as the second most
common symptom [2,9]. Urinary obstruction, abdominal
pain, urinary tract infection and weigh loss have been
reported occasionally [4,5,9]. Rare cases of paraneoplas-
tic syndromes such as ectopic ACTH secretion and
hypercalcaemia were also reported [5,21].
IV - Diagnosis
Diagnosis of SCCB is mainly accomplished via histo-
pathological examination of specimens obtained by
cystoscopy and transurethral resection of the bladder
tumour (TURBT) [22]. Immunochemistry staining is
extremely helpful in establishing the diagnosis. The role
of molecular biology has not yet been defined.
(A) Histopathology
In histological studies, SCCB are identical to SCLC.
Therefore, the diagnosis is based on the criteria estab-
lished by the WHO classification system (2004), used
for the diagnosis of SCLC. In light microscopy, morpho-
logical studies of SCCB sections stained with haematox-
ylin and eosin showed packed cells having scant
cytoplasm containing few organelles. Tumour is com-
posed of nests of small round malignant cells with
pyknotic round to oval nuclei and evenly dispersed “salt
and pepper chromatin” (Figure 1A, B and 1C) [9]. The
mitotic rate is high (> 10 mitotic figures ⁄ 10 high-power
fields) in 57% of the cases. Tumour rosettes were seen
in 23.5% of the cases. Tumour necrosis was present in
the majority of the cases. Crush artefact (Azzopardi
effect) was found in 78.4% of the cases. Vascular inva-
sion was present in 16.7% of the cases [9]. In most
reports, the authors showed a higher incidence of mixed
SCC [2-10,15]. In Abrahams study, mixtures of SCC
Figure 1 Pathology of small cell carcinoma of the bladder [31,43]. A. Hematoxylin and eosin (H and E) staining of the biopsy specimen, low-
power view: Urothelial mucosa unfiltered by poorly differentiated carcinomatous proliferation comprised sheets of monomorphic cells. B.
Hematoxylin and eosin (H and E) staining of the biopsy specimen, high-power view (×20): Proliferation comprised small cells with
hyperchromatic nuclei infiltrating the muscle. C. Hematoxylin and eosin (H and E) staining: High-power view (×40) of a transurethral resection of
small cell carcinoma, showing typical scant cytoplasm, increased mitotic index, spindling, and prominent nuclear moulding. D. Immunostaining:
NSE-antibody-positive bladder tumor cells
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the cases, while mixtures of SCC with adenocarcinoma
and squamous carcinoma were present only in 8% and
10% of the cases respectively [9].
(B) Immunohistochemistry
Immunohistochemistry has a central role for the diagno-
sis of SCCB through the staining of tumour components
by antibody markers targeting the following antigens:
neuron-specific enolase (NSE), chromogranin, synapto-
physin, serotonin, cytokeratin, S-100 protein, TTF1,
EGFR and C-KIT (table 2) [2,9,11,23-28]. The most
expressed markers would result on an intense staining
of the cytoplasm: NSE (with a frequency of 88.5%) (Fig-
ure 1D), synaptophysin (72.4%), and chromogranin
(50%) [2,9,11,23]. SCCB are also stained with the epithe-
lial markers: CAM 5.2, CK7, and EMA in 59%, 41%, and
77.7% of the cases, respectively. This supports the
urothelial origin of SCCB [2,9,11,24]. TTF-1 expression
in SCCB was found in 40% of the tumours in 2 studies,
demonstrating that this marker can be expressed in
SCC other than those of pulmonary origin [24,25].
Immunochemistry staining of EGFR and C-KIT showed
weak cytoplasmic staining in 30% and 27% of the cases,
respectively [9,26,27]. PDGFRA expression was reported
in one case [28].
(C) Molecular genetics
Genetic alterations in SCCB have been the subject of
few studies, because of the rarity of the disease. A Com-
parative genomic hybridization (CGH) study has demon-
strated chromosomal deletions at 10q, 4q, 5q and 13q
[18,29]. These regions are frequently deleted in human
tumours and known to carry some tumour suppressor
genes: PTEN located at 10q23 and the retinoblastoma
gene located at 13q14 [30]. Additions of DNA sequences
have been reported at 5p, 6p, 8q and 20q [18,29]. How-
ever, no clear single genetic lesion has been character-
ized. Other studies are necessary to define the role of
molecular genetics in the diagnosis of SCCB.
V - Bladder small cell cancer imaging
As for TCC of the bladder, the most widely used ima-
ging examination of SCCB is the pelvic computed tomo-
graphy scan of the bladder mass and the locoregional
extension (bladder wall and pelvic lymph nodes).
VI - Staging
In most cases, the diagnosis is made at advanced stages
(T3-T4/N+/M+) (Figure 2A) [31]. More than 95% of
SCCB cases are diagnosed at muscle invasive stage T2
or more [5-9,11,12]. As an example, in a large MD
Anderson series of 88 cases, only 4.5% (4 patients) were
diagnosed at superficial stage of the disease (Ta/T1),
while 40.1% (n = 36) were diagnosed at stage T2, 28.3%
(n = 25) were diagnosed at stage T3-T4a (stage III) and
26.1% (n = 23) were diagnosed at stage T4b-M+ (stage
IV) [12]. Similar findings were observed in three others
larges series [5,8,11]. As for bladder TCC, the TNM-sta-
ging system was commonly used for SCCB
[2,3,5-8,14,12,32,33]. Patients with SCCB restricted to
the bladder, should be considered as having surgically
resectable disease (≤T1-4aN0M0) [33]. In this case,
treatment with neoadjuvant chemotheapy followed by
surgery is favored. Patients with regional or non regional
lymph nodes (retroperitoneal lymph nodes or distant
lymph nodes) or with distant metastasis have the disease
at advanced stage (surgically unresectable disease)
(≥cT4bN+M+) [33]. Systemic chemotherapy is the treat-
ment of choice for these patients.
Based on two large studies, the most frequent sites of
metastasis were pelvic and retroperitoneal lymph nodes
(28.6% - 53%), liver (23.8% - 47%) (Figure 2B), bone
(23.8 - 33%), brain (7.9% - 16%) and lung (9.5% - 13%)
[5,12]. Consequently, the staging of SCCB should
include computed tomography scan of the pelvis, abdo-
men chest, brain, and bone scan.
VII - Differential diagnosis
SCCB must be differentiated from several other cancers
[23]:
Table 2 Immunohistochemistry findings in small cell
carcinoma of the urinary bladder.
Antibody No of
studies
% of positives staining
(mean)
Neuroendocrine markers
NSE[2,9,11,23] 4 25-100% (88.5%)
Synaptophysin[2,11,9] 3 66.6-76% (72.4%)
Serotonin[23] 1 78%
Chromogranin
[2,9,11,17]
4 22-89% (50%)
Epithelial markers
Cytokeratin[2,23] 2 70-77% (75%)
EMA[2] 1 77.7%
CK7[24] 1 59%
CAM 5.2[2,11,9] 3 47-66.6% (41%)
Other markers
S-100 protein[23] 1 40%
TTF1[24,25] 2 39-50% (40%)
EGFR[9,26] 2 27-36% (28.6%)
C-KIT[9,27] 2 22-27% (27%)
CD44v6[11] 1 7%
PDGFR[28] 1 case report +
Abbreviations. NSE = neuron specific enolase; EMA = epithelial membrane
antigen; CK7 = cytokeratine 7; EGFR = epidermal growth factor receptor;
PDGFR = platelet derived growth factor
Ismaili Orphanet Journal of Rare Diseases 2011, 6:75
http://www.ojrd.com/content/6/1/75
Page 4 of 11*Direct invasion of the bladder by SCC of the prostate;
prostatic small cell carcinoma is typically negative for
prostate-specific antigen.
*Metastatic SCC from another source, usually from
the lung. Metastatic SCLC may not be distinguishable
histologically from a primary SCCB; however, the pre-
sence of TCC component (including TCC in situ) would
support a diagnosis of bladder SCC.
*Primary lymphomas of the bladder; lymphomas are
positive for leukocyte common antigen (LCA), and
negative for keratin and neuroendocrine markers.
VIII - Disease management
Because of the rarity of SCCB, there is no standard
treatment of the disease. SCCB is an aggressive tumour
(90% of patients are at stage II or more and 25% are at
stage IV). This favours the use of chemotherapy (CT) in
the management of the disease [12]. Table 3 summarizes
the most important studies addressing the management
of SCCB.
(A)Radical resection
In contrast with SCLC, more than half of the patients
with SCCB undergo radical resection [3,5-8,12]. In a
review of 88 cases, reported by MD Anderson Cancer
Centre, 46 patients undergone cystecomy [12]. Similarly
in two other studies, the radical resection was per-
formed in 60 to 70% of the cases [5,8]. Surgery was
favoured because of the frequent combination of SCC
with TCC. In fact, in one study, 60% of the patients hav-
ing SCCB developed TCC, 24 to 26 months after the
completion of curative chemo-radiotherapy (CRT) [4].
However, in a multi-institutional review of 64 patients
with localised SCCB, the efficacy of cystectomy has been
questioned as no survival difference was found between
patients undergoing surgery and those without surgery
(5-year survival was 16% vs. 18%, respectively) [8]. Sur-
gery alone is not appropriate to achieve cure for patients
with SCCB. In the retrospective study conducted by MD
Anderson, the patients who received neoadjuvant CT
have significantly better survival than those who did not
receive neoadjuvant CT [12].
(B)Radiotherapy
In general, SCLC is treated with a combination of radio-
therapy (RT) and CT. In analogy to SCLC, RT either
alone or in combination with CT, was used to treat
SCCB at localised disease [3,4,10,15,32].
Three retrospectives studies with longer follow-up (5
years), have assessed the role of curative RT in the man-
agement of localised bladder SCC [3,4,15]. In the first
study (n = 25), a group of 18 patients received surgery
and curative radiotherapy (without chemotherapy) [3].
In the 2 others studies, 10 and 17 patients, respectively,
received sequential chemo-radiotherapy [3,4]. The 5
years survival was equal to 28%, in the first study, vs.
7 0 %a n d3 6 %i nt h es e c o n da n d third studies, respec-
tively [3,4,15]. Long-term survivors have been reported
(up to 18 years) [3], however, those with longer follow-
up suggest a higher likelihood of relapse over time [4].
These results confirmed that radiotherapy can be cura-
t i v e ,b u ts i g n i f i c a n t l ym o r ec u r a t i v ew h e nu s e di nc o m -
bination with chemotherapy.
(C) Chemotherapy
Chemotherapy is the major treatment modality for
SCCB [34,35]. In one large series, the authors showed
on multivariate analysis that cisplatin chemotherapy is
the only predictor factor for survival of SCCB patients
(p < 0.0001) [35]. In surgically resectable disease che-
motherapy is used as neoadjuvant therapy to shrink the
Figure 2 Bladder small cell carcinoma imaging [31]. A. Computed tomography scan of the pelvis shows a heavy tumor at the right bladder
wall with intraluminal and extravesical extension (arrows). B. Computed tomography scan of the abdomen shows a multinodular liver disease
from bladder small cell carcinoma (arrows).
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published in the English literature.
Authors No Study
design
Stages (No) Treatments (No) Results and comments
Blomjous 1989 [2] 18 Retrospective T2(5)
T3(8)
T4(5)
CT
group
TURBT®RT®CT
(2)
TURBT®CT(1)
RC®CT(1)
CT®RC(1)
-OS and 2 years survival in the whole group = 9 months
and 27.7% respectively
-OS and Survival at 2 years in CT group vs. no CT group
= NR vs. 7 months and 60% vs. 15.5%, respectively
Non-CT
group
TURBT®RT(9)
RC(3)
None(1)
Holmang 1995 [3] 25 Retrospective T2(7)
T3(10)
T4(2)
IVM+(6)
RC®RT(18)
CT(2)
None(5)
5 years survival in the whole group = 20%
Lohrisch 1999 [4] 14 Retrospective LD(9)
ED(1)
CT
group
CT®RT(8)
CT®RC(1)
CT®C(1)
-OS in the CT grope = 41 months
-Survival at 5 years = 70% in the CT group vs. 0% in the
non CT group
LD(2); ED(2) Non-CT
group
RT(2)
None(2)
Bastus 1999 [32] 5 Retrospective T2(1)
T3(3)
T3N1(1)
CT®RT(5) -All patients were treated with sequential chemo-
radiotherapy;
-2 years survival in the whole group = 80%
Siefker-Radtke 2004
(MD Anderson) [12]
46 Retrospective
cohort
T2(13)
T3-T4a(8)
CT®RC(21) 5 years survival in neoadjuvant CT group was significantly
better than surgery alone group = 78% vs. 36%, p = 0.026
T2(12)
T3-T4a(7)
Unknown(n = 6)
RC(25)
Cheng 2004 [8] 64 Retrospective
cohort
T1(1)
T2(30)
T3(29)
T4(4)
RC(38)
RT(10)
CT(23)
No difference in survival between RC group vs. non-RC
group
Mangar 2004 [14] 14 Retrospective T3(8)
T3N1(1)
T4 (2)
IVM+(3)
RC
group
RC®CT®RT(1)
RC®RT(3)
RC(2)
Outcome in RC group > outcome in non-RC group
Non-RC
group
PRT(5)
None(3)
Choong 2005
(Mayo Clinic) [5]
44 Retrospective II(12) RC(7)
NCT®RC(1)
PC(3)
-5 years survival in the whole group = 25%
-5 years survival in stage II > III/IV = 63%, 15%, and 10%
respectively, p< 0.001;
-No difference between stages III and IV
III(13) RC(8)
RC®CT(2)
IV(19) RC®CT(10)
RC(2)
CT(5)
Bex 2005 [10] 25 Prospective LD(10)
ED(3)
CT
group
CT(13)®RT(8) CT > non-CT (OS = 15 vs. 4 months respectively, p =
0.003)
LD(7)
ED(5)
Non-CT
group
RT(5)
RC(3)
P(4)
Quek 2005 [6] 25 Retrospective I/II(4)
III(2)
IV N+ or M+(19)
RC®ACT(13)
NCT®RC(1)
RC(11)
-Survival in mixed SCCB > survival in pure SCCB, p = 0.06
-RC + ACT > RC alone
Mukesh 2008 [13] 20 Retrospective LD(11); ED(9) CT
group
(13)
CT®RT(6)
RC®CT(7)
Outcome in CT group > outcome in non-CT (OS = 33
months vs. 3 months, respectively)
Non-CT
group
(7)
BSC(4)
RC(4)
RT(1)
Ismaili Orphanet Journal of Rare Diseases 2011, 6:75
http://www.ojrd.com/content/6/1/75
Page 6 of 11tumour prior to local therapy or as adjuvant treatment
after surgical resection [5,12].
Neoadjuvant chemotherapy Neoadjuvant CT before
surgery in surgically resectable SCCB has been investi-
gated in several retrospective studies and in one phase
II prospective study [12,33]. In addition primary CT was
used in sequence with radiation to increase the efficacy
of RT [4,10,15,32].
Neoadjuvant CT in bladder SCC cancer has four
theoretical advantages [36,37]:
*the early treatment of micrometastatic disease,
*the systemic treatment is better tolerated by allow-
ing the preoperative administration of CT drugs in
optimal doses with less toxicity,
*SCCB is highly chemosensitive disease; the vast
majority of patients have great responses,
*downstaging, which facilitates the surgical
techniques.
One retrospective cohort study and one phase II
clinical trial demonstrated the advantage of CT in
neoadjuvant setting.
In the MD Anderson retrospective study, 46 operable
patients were included; the first group of patient (n =
21) was treated with 4 cycles of neoadjuvant sequential
CT regimen based on ifosfamide plus doxorubicin at
day 1 repeated every 42 days and etoposide plus
cisplatin at day 21 repeated every 42 days; the second
group was treated with surgery alone (n = 25). At last
follow-up, 5-year survival was significantly higher in CT
group: 78% versus 36% in surgery alone group (p =
0.026) [12]. In addition, the results of the MD Anderson
phase II clinical trial recently published, confirmed the-
ses results. In this prospective study, 30 eligible patients
were included, eighteen of them were surgically resect-
able and 12 were surgically unresectable. Operable
patients have been treated with neoadjuvant CT fol-
lowed by surgery. At last follow-up, OS and 5 years sur-
vival in resectable group was equal to 58 months and
80%, respectively [33].
Based on these data, neoadjuvant CT should be con-
sidered as the treatment of choice of surgically resect-
able SCCB.
Adjuvant chemotherapy No clear data defines the role
of adjuvant CT after primary surgery of invasive bladder
SCC. Only one retrospective study conducted by the
University of Southern California has addressed this
question. In the published article, the authors concluded
that adjuvant CT may provide improved survival com-
pared with cystectomy alone [6]. In addition, the Mayo
Clinic recommendations propose cystectomy alone for
patients with stage II disease, and adjuvant chemother-
apy for patients with stage III and VI (M0) disease [5].
However, it is important to note that many institutions
who followed the Mayo recommendations of initial
Table 3 Treatment strategies and outcome of bladder small cell carcinoma according to the most important studies
published in the English literature. (Continued)
Ismaili 2008 [7] 14 Retrospective II(4)
III(5)
IVM0(5)
RC®CT(4)
RC(5)
CT®RC(2)
CT(1)
RCT(1)
None(1)
-Survival in mixed SCCB > survival in pure SCCB, p = 0.01,
-CT + Surgery > Surgery
Bex 2009 [15] 17 Retrospective LD(17):
-T2(14)
-T3(2)
-T4a(1)
CT®RT (60: 56-70Gy) (17)
Salvage RC (3)
-All patients have been treated with sequential
chemoradiotherapy
-OS = 32.5 months
-2, 3, and 5 years survival = 56%, 47%, and 36%
respectively
Siefker-Radtke 2009
(MD Anderson) [33]
30 Phase II Resecable patients
(18): T2N0M0
CT®RC -5 years survival in operable group = 80%
-OS = 58 months vs 13.3 months, in operable vs non
operable patients, respectively
-Incidence of brain metastasis in stage III/IV = 50%
Unresecable
patients(12): T3b-
4aN0M0
CT alone
Bex 2010 [40] 51 Retrospective LD(39) CT®RT -Survival of patients with LD = 35 months vs 6 months in
patients with ED.
-Incidence of brain metastasis = 10.5%
ED(12) CT
Abbreviations. OS = overall survival; NS = no significant; RC = radical cystectomy; TURBT = transurethral resection of the bladder tumour; ACT = adjuvant
chemotherapy; NCT = neoadjuvant chemotherapy; PC = partial cystectomy; CT = chemotherapy; RCT = concurrent chemoradiotherapy; PRT = palliative
radiotherapy; NR = no reached; LD = limited disease; ED = extensive disease; SCCB = small cell carcinoma of the bladder; Definition for LD (limited disease): in
analogy to SCLC, patient with any local stage, no distant metastases and involvement of maximally one loco regional lymph node less than 2 cm in imaging (cTx
cN0-1 M0) [15]; Definition for ED (extensive disease): unresectable and metastatic disease [15].
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hood of upstaging [5,6].
Chemotherapy in advanced disease When SCCB arise
outside the bladder, CT plays a prominent role in the
management of these tumors. In metastatic setting, the
most commonly used regimen for SCCB is cisplatin plus
etoposide CT in analogy to SCLC [5,12,15]. Etoposide is
administered at 100 to 120 mg/m
2 intravenously on day
1 to 3, repeated every 3 weeks. Cisplatin is usually given
at 70 to 100 mg/m
2 intravenously on day 1. The MD
Anderson group showed that preoperative CT with a
neuroendocrine regimen was more likely to successfully
eradicate the small cell component compared to regi-
mens typically used for TCC. In fact, of the 12 patients
treated with a neuroendocrine regimen only 2 had small
cell carcinoma present at cystectomy. However, for
those 9 patients treated with a transitional cell carci-
noma regimen (MVAC) 6 had small cell carcinoma still
present at cystectomy [12]. Consequently, this group
recommended the protocols used in the neuroendocrine
tumours containing etoposide and cisplatin or ifosfa-
mide and doxorubicin for both histological types: pure
SCC and mixed SCC [38]. Other authors recommended
a regimen covering both small cell component and TCC
component for mixed SCCB: the addition of taxane or
ifosfamide to the standard platinum plus etoposide regi-
men may be considered [39]. In the unfit patient, cispla-
tin should be substituted with carboplatin.
Other chemotherapy regimens including etoposide-cis-
platine alternating protocol either with ifosfamide-dox-
orubicin or with cyclophosphamide, doxorubicin and
vincristin (CAV), as well as single agents, including
paclitaxel, irinotecan, topotecan, and doxorubicin, have
all been used in SCCB [5,12]. Table 4 summarizes the
most used regimen in the management of SCCB.
(D) Nervous system and bone metastasis
Based on the high efficacy of chemotherapy against
metastatic small cell carcinoma, palliative radiotherapy
is rarely adopted. However, radiotherapy is reserved for
treatment of symptomatic brain metastases, sympto-
matic bone metastases and cord compression. According
to a recent retrospective investigation, the incidence of
symptomatic brain metastases from SCCB is signifi-
cantly lower than that from SCLC. Therefore, the
authors do not recommend systematic prophylactic
brain irradiation (PCI) in patients with SCCB [40]. In
another hand, the authors at MD Anderson, report in
the phase II clinical trial a 50% incidence of brain
Table 4 Chemotherapy regimens used in the treatment of SCCB
Regimen Schedule Drugs and doses
First line
EP (IV)
[5,10,15,33]
On day 1 to 3, repeated after 21 days Etoposide 120 mg/
m
2 on day 1 to 3
Cisplatin 80-
100 mg/m
2 ,
on day 1
IA/EP (IV)
[12,33]
Alternative regimen: ifosfamide plus
doxorubicin on day 1 to 3 repeated every 42
days and etoposide plus cisplatin on day 22 to
26 repeated after 42 days
Ifosfamide 2 g/m
2 ,
on day 1 to 3
Doxorubicin
25 mg/m
2 ,
on day 1 to
3
Etoposide 80 mg/
m
2 , on day 22 to
26
Cisplatin 20
mg/m
2 ,o n
day 22 to 26
VIP (IV)[10] On day 1 to 4, repeated after 21 days Ifosfamide 1.2 g/m
2
,o nd a y1t o4
Etoposide 75
mg/m
2 on
day 1 to 4
Cisplatin 20 mg/m
2
on day 1 to 4
EP/CAV (IV)
[11]
Alternative regimen: EP on day 1 to 3 repeated
after 42 days and CAV on day 22 repeated
every 42 days
Etoposide 100 mg/
m
2 on day 1 to 3
Cisplatin 80
mg/m
2 ,o n
day 1
Cyclophosphamide
800 mg/m
2 on day
22
Doxorubicine
50 mg/m
2 on
day 22
Vincristine
1.4 mg/m
2
on day 22
MVAC (IV)
[12]
On day 1, 2, 15, and 22, repeated every 28 days Methotrexate 30
mg/m
2 on day 1,
15 and 22
Vinblastine 3
mg/m
2 on
day 2, 15,
and 22
Doxorubicin 30
mg/m
2 on day 2
Cispatin 70
mg/m
2 on
day 2
Second line
Topotecan
(IV)[5]
On day 1 to 5, repeated every 21 days Topotecan 1.5 mg/
m
2 on day 1 to 5
CAV (IV) On day 1, repeated every 21 days Cyclophosphamide
800 mg/m
2 on day
1
Doxorubicin
50 mg/m
2 on
day 1
Vincristine 1.4 mg/
m
2 on day 1
Vinorelbine
(IV)[41]
On day 1, 8, and 15. The cycle is repeated every
21 days
Vinorelbine 25 mg/
m
2 on day 1, 8,
and 15
IV = intravenous
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Page 8 of 11metastases in patients with stage III-IV disease; this
information suggests a possible group to consider for
PCI [33].
(E) Progressive or relapsing disease
In analogy to SCLC, the likelihood of response to
further CT can be predicted on the basis of the response
to previous therapy and the duration of free interval.
Patients who did not respond to previous therapy or
who relapsed within 3 months are judged refractory. For
patients with sensitive disease, the same induction regi-
men can be used for treatment. Three weekly vinorel-
bine has been tested in a case series and has showed an
interesting activity [41]. Second-line regimens are sum-
marized in table 4.
(F) Future directions
Despite the promising results obtained by chemotherapy
based on cisplatin, the majority of patients die of meta-
static disease.
The progress in molecular biology has led to the
investigation of new molecules in several primary
tumours including SCLC. Overexpression of several
receptors such as the VEGFR (vascular endothelial
growth factor receptor) on endothelial cells, the EGFR
(epidermal growth factor receptor, the c-KIT, the
PDGFR (platelet derived growth factor receptor) and the
FGFR (fibroblast growth factor receptor), on tumor cells
has prompted the scientific community to evaluate the
efficacy and safety of new molecules targeting signaling
pathways controlled by these proteins in metastatic
SCLC (bevacizumab, sunitinib, sorafenib, pazopanib,
Imatinib, cetuximab, erlotinib, Gefitinib, lapatinib, evero-
limus, bortezomib) (Figure 3). According to preliminary
studies, targeting angiogenesis would be the most pro-
mising strategy [42]. In analogy to SCLC, the role of
theses molecules in metastatic SCCB should be defined
in the future.
Figure 3 Deregulated signaling pathways and targeted therapy which should be evaluated in the future in SCCB in analogy to SCLC.
Abbreviations: EGFR, Epidermal Growth Factor Receptor; VEGFR, Vascular Endothelial Growth Factor R; FGFR: Fibroblast Growth Factor Receptor;
PDGFR, Platelet Derived Growth Factor Receptor; mTOR: mammalian Target of Rapamycin.
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Page 9 of 11IX-Treatment recommendations [39,43-45]
(A) Surgically resectable disease
Neoadjuvant chemotherapy followed by radical resection
should be considered as the treatment of choice in sur-
gically resectable SCCB. This sequence can achieve a
cure in 78-80% of the patients [12,33];
Sequential chemo-radiotherapy is a second treatment
option which can achieve a cure in 36 to 70% of the
cases [4,15];
In the case when surgery was performed first, adjuvant
chemotherapy or adjuvant chemo-radiotherapy should
be indicated [5,6];
(B) Advanced disease
In advanced stages, chemotherapy based on cisplatin
should be considered as the treatment of choice for
patients with good performance status (0-1) and good
renal function-Glomerular filtration rate (GFR) > 60
mL/min. The treatment should be based on neuroendo-
crine regimens type etoposide plus cisplatin or the
sequential protocol; ifosfamide plus doxorubicin at day
1 and etoposide plus cisplatin at day 21 (table 4). In
unfit patients, cisplatin should be substituted by carbo-
platin AUC 5 to 6.
X-Prognosis
The prognosis of SCCB is poor. Five-year survival rate
of all stages combined is equal to 19% (16 to 25%) [5,8].
Based on one large study, the 5-year survival rates for
patients with Stage II, III, and IV were 63.6%, 15.4%,
and 10.5% respectively. Advanced stages III and IV have
poorer outcome than stage II disease; P< 0.0001 [5]. In
addition, according to 2 series, pure small cell histology
was shown to have poorer outcome than the mixed
small cell histology [6,7,34]. Because of the rarity of this
disease, no others prognostic factors were identified.
XI-Conclusions
Primary SCCB is a rare and aggressive tumour. In more
than 50% of the cases, the diagnosis is performed at
advanced stages III/IV. Demographic and clinical fea-
tures are comparable to those of bladder TCC. The ori-
gin of disease is not clearly defined; but the multipotent
theory is the most accepted. Criteria of pathological
diagnosis and radiological work-up are similar to those
of SCLC. Coexistence of SCCB with other types of car-
cinoma is common. Immunochemistry plays a major
role in the diagnosis using the markers of neuroendo-
crine tumours. The staging system mostly used is the
TNM-staging system of bladder TCC. The best treat-
ment for this tumour was not established for certain;
only one prospective study was published up to now.
The strategy of therapy was extrapolated from SCLC. In
surgically resectable disease, the management should
include multimodal therapy with chemotherapy first fol-
lowed by radical resection or radical radiotherapy. In
advanced disease, chemotherapy using platinum agent
(cisplatin in fit patients) is the mainstay treatment. The
prognosis of SCCB is poor. Pure small cell histology
shows to have worsened prognosis than the mixed small
cell histology. Further investigations are needed to
improve our knowledge in the diagnosis and treatment
of this rare disease.
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